Apnimed is exploding higher as investors continue to react to the bullish initiation of coverage by BofA Securities on August 25. The firm assigned a Buy rating and a $41 price target to the stock, citing a risk-adjusted discounted cash flow analysis of the company's sole asset, Oxnimbi. While the broader healthcare sector has been dominated by news regarding the FDA approval of a new pancreatic cancer drug, this development is specific to Revolution Medicines and does not directly impact Apnimed's current momentum.